Healy Proclaims Her Long-Range Objective: Rapid Escalation In Number Of NIH Grants

Clearly established research goals, awards of shorter duration, and vigilance over costs will do the trick, says the agency,s director BETHESDA, Md.--National Institutes of Health director Bernadine Healy hopes to increase by almost 50 percent the total number of grants the agency awards over the next several years. To do it, she says, NIH must trim budget requests by principal investigators and tighten up on indirect costs paid to institutions, manipulate the length of its grants awarded to av

Written byJeffrey Mervis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

If successful, the plan over time could have a major impact on the way that scientists obtain their funding from the agency.

This year NIH will fund more than 21,000 research project grants, a number that has grown very slowly over the past several years. Healy, who became director in April, wants that number to top 30,000 annually by the end of the decade as part of a major campaign to increase federal support for her agency. At the same time, she and other NIH officials would like to see the success rate of applicants rise to at least one in three, from the current level of one in four. While those goals won't be achievable without additional money, Healy says, it will ensure that NIH sets ambitious objectives for itself and then works hard to meet them.

"What's happened to [the size of] our portfolio [of grants] over the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies